Although the biotech has only conducted preclinical studies so far, there are several potential advantages to
nonviral therapies, including being quicker to develop and possibly eliminating the need for a lengthy monitoring period of patients after treatment.
Not exact matches
Zarogoulidis P, Hohenforst - Schmidt W, Darwiche K. et al. 2 - diethylaminoethyl - dextran methyl methacrylate copolymer
nonviral vector: still a long way toward the safety of aerosol gene
therapy.
Biotech company Eyevensys has received approval from the French national regulatory agency ANSM to advance its
nonviral gene
therapy platform to clinical development.